Inside informationEnglish
Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study
The file is served by the AMF. We do not host a copy.
Document type
- Issuer
- Sanofi
- Filed
- 15/06/2025, 17:22
- Document type
- Inside information
- AMF sub-type
- Informations privilégiées
- Language
- English
- AMF reference
- 112745_20250615